Healthcare
Live Price
Offline$17.54
+2.81% today
1Y Change
-29.56%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stevanato Group S.p.A. (STVN) is a Healthcare stock with a market cap of $4.12B and listed on NYSE. The stock last traded around $17.54 and down 29.6% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +3.2%, EPS growth of +14.0%, a dividend yield of 0.3%. What stands out right now is revenue +3.2%, EPS +14.0%, free cash flow +113.6% with operating margin 16.5% and ROIC 6.8%. The dividend is present but secondary, with a yield around 0.3%. Valuation is more restrained than many high-expectation growth names at P/E 29.5 and price/sales 3.5. Stock Foundry combines STVN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STVN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STVN Max Drawdown
-51.95%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STVN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$843.9M
-14.2% YoY
FY Net Income
$134.3M
-6.0% YoY
Free Cash Flow
$20.2M
+114.4% YoY
Revenue Growth
+3.2%
EPS Growth
+14.0%
Gross Margin
29.0%
Net Margin
11.8%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.1B | 984M | 844M |
| Gross Profit | 330M | 302M | 340M | 320M | 265M |
| Operating Income | 183M | 161M | 201M | 192M | 162M |
| EBITDA | 268M | 248M | 272M | 256M | 227M |
| Net Income | 134M | 118M | 146M | 143M | 134M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 131M | 98M | 70M | 229M | 411M |
| Total Assets | 2.5B | 2.3B | 2.1B | 1.7B | 1.4B |
| Total Liabilities | 1.1B | 924M | 939M | 664M | 577M |
| Shareholder Equity | 1.5B | 1.4B | 1.1B | 996M | 842M |
| Total Debt | 471M | 429M | 397M | 218M | 244M |
| Net Debt | 340M | 331M | 327M | -10M | -167M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
133M
+29.1% YoY
Capital Expenditures
113M
+53.4% YoY
Free Cash Flow
20M
+114.4% YoY
Key ratios
Gross Margin
29.0%
Operating Margin
16.5%
Net Margin
11.8%
ROE
9.7%
Debt / Equity
0.32x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.